<DOC>
	<DOCNO>NCT00677326</DOCNO>
	<brief_summary>The purpose study evaluate safety time progression HLA-A*0201 restrict epitope peptide VEGFR1 VEGFR2 emulsify Montanide ISA 51 advance breast cancer patient .</brief_summary>
	<brief_title>Histocompatibility Leukocyte Antigen ( HLA ) -A*0201 Restricted Peptide Vaccine Therapy Patients With Breast Cancer</brief_title>
	<detailed_description>VEGF receptor 1 2 essential target tumor angiogenesis , identify peptide derive receptor significantly induce effective tumor specific CTL response vitro vivo . According finding , trial , evaluate safety , immunological clinical response peptide . Patients vaccinate twice week 8 week . On vaccination day , VEGFR1 peptide ( 1mg ) VEGFR2 peptide ( 1mg ) mixed Montanide ISA 51 administer subcutaneous injection . Repeated cycle vaccine administer patient develop progressive disease unacceptable toxicity , whichever occur first . In phase I study , evaluate safety tolerability peptide vaccine . In follow phase II study , evaluate immunological clinical response vaccine therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Advanced recurrent breast cancer Resistant anthracyclinebased taxanebased chemotherapy difficult continue chemotherapy due intolerable side effect ( ) Resistant trastuzumab difficult continue due intolerable side effect ( ) her2 positive ECOG performance status 02 Life expectancy &gt; 3 month HLAA*0201 Laboratory value follow 2000/mm3 &lt; WBC &lt; 15000/mm3 Platelet count &gt; 100000/mm3 Bilirubin &lt; 3.0mg/dl Asparate transaminase &lt; 150IU/L Alanine transaminase &lt; 150IU/L Creatinine &lt; 3.0mg/dl Able willing give valid write informed consent Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) Breastfeeding Active uncontrolled infection Unhealed external wound Concurrent treatment steroid immunosuppressing agent Prior chemotherapy , radiation therapy , immunotherapy within 4 week Uncontrolled brain and/or intraspinal lesion ( ) Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>HLA-A*0201</keyword>
	<keyword>Peptide Vaccine</keyword>
	<keyword>VEGFR1</keyword>
	<keyword>VEGFR2</keyword>
</DOC>